OmniAb, owned by Ligand Pharmaceuticals, has entered into a merger agreement with SPAC Avista Public Acquisition Corp. II. Avista now has $266 million in its escrow account. Ligand shareholders will own 75% to 84% of the combined company, and its shares will trade on the Nasdaq under the ticker symbol OABI.
OmniAb, owned by Ligand Pharmaceuticals, has entered into a merger agreement with SPAC Avista Public Acquisition Corp. II. Avista now has $266 million in its escrow account. Ligand shareholders will own 75% to 84% of the combined company, and its shares will trade on the Nasdaq under the ticker symbol OABI. 
investor.ligand.com
English (US) 